Attached files
| file | filename |
|---|---|
| EX-99.1 - Molecular Templates, Inc. | v211762_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 25, 2011 (February 16,
2011)
THRESHOLD
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32979
|
94-3409596
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
1300
Seaport Boulevard, Suite 500
Redwood
City, California 94063
(Address
of principal executive offices)(Zip Code)
(650)
474-8200
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
On
February 16, 2011, Threshold Pharmaceuticals, Inc. issued a press release
announcing that the Company reached agreement with the U.S. Food and Drug
Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3
randomized trial of TH-302 in patients with soft tissue sarcoma. The
press release is attached as Exhibit 99.1 to this Form 8-K.
.
Item
9.01 Financial
Statements and Exhibits.
(d)
Exhibits
Exhibit
99.1 Press
release dated February 16, 2011.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
THRESHOLD
PHARMACEUTICALS, INC.
|
|||
|
|
By:
|
/s/ Joel A. Fernandes | |
| Joel A. Fernandes | |||
| Senior Director, Finance and Controller | |||
Date: February
25, 2011
Exhibit
Index
Exhibit
No. Description
Exhibit
99.1 Press
release dated February 16, 2011.